Article Text

Download PDFPDF
Original research
S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development
  1. Cyril Sobolewski1,
  2. Daniel Abegg2,
  3. Flavien Berthou1,
  4. Dobrochna Dolicka1,
  5. Nicolas Calo1,
  6. Christine Sempoux3,
  7. Margot Fournier1,
  8. Christine Maeder1,
  9. Anne-Sophie Ay1,
  10. Pierre-Alain Clavien4,
  11. Bostjan Humar5,
  12. Jean-François Dufour6,
  13. Alexander Adibekian2,
  14. Michelangelo Foti1
  1. 1 Department of Cell Physiology and Metabolism, University of Geneva Faculty of Medicine, Geneve, GE, Switzerland
  2. 2 Department of Chemistry, The Scripps Research Institute, Jupiter, Florida, USA
  3. 3 Department of Clinical Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  4. 4 Visceral and Transplantation Surgery, University Hospital of Zurich, Zurich, Switzerland
  5. 5 Department of Surgery, University Hospital Zurich, Zurich, Switzerland
  6. 6 Department of Hepatology and Clinical Research, University of Bern, Bern, Switzerland
  1. Correspondence to Professor Michelangelo Foti, Department of Cell Physiology and Metabolism, University of Geneva Faculty of Medicine, Geneve 1206, Switzerland; michelangelo.foti{at}


Objective Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations.

Design The proteome of steatotic liver tissues from mice spontaneously developing HCC was analysed. Alterations of TSs/ONCs were further investigated in various mouse models of NAFLD/HCC and in human samples. The inflammatory, fibrogenic and oncogenic functions of S100A11 were assessed through in vivo, in vitro and ex-vivo analyses.

Results A whole set of TSs/ONCs, respectively, downregulated or upregulated was uncovered in mice and human with NAFLD. Alterations of these TSs/ONCs were preserved or even exacerbated in HCC. Among them, overexpression of S100A11 was associated with high-grade HCC and poor prognosis. S100A11 downregulation in vivo significantly restrains the development of inflammation and fibrosis in mice fed a choline/methionine-deficient diet. Finally, in vitro and ex-vivo analyses revealed that S100A11 is a marker of hepatocyte de-differentiation, secreted by cancer cells, and promoting cell proliferation and migration.

Conclusion Cellular stress associated with NAFLD triggers non-genomic alterations of a whole network of TSs/ONCs fostering hepatocarcinogenesis. Among those, overexpression of the oncogenic factor S100A11 promotes inflammation/fibrosis in vivo and is significantly associated with high-grade HCC with poor prognosis.

  • hepatocellular carcinoma
  • oncogenes
  • tumour markers
  • nonalcoholic steatohepatitis
  • fatty liver

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @dufour_jf

  • Contributors CSo: study concept and design; acquisition, analysis and interpretation of data; drafting of the manuscript; DA, FB, DD, NC, CSe, MaF, CM and A-SA: acquisition, analysis and interpretation of data. P-AC, J-FD, BH and AA: interpretation of data and critical revision of the manuscript for important intellectual content. MiF: study concept and design, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, funding, study supervision. All authors critically revised the manuscript and approved its final version.

  • Funding This work was supported by the Swiss National Science Foundation (Grant no. 310030-172862 and CRSII3-160717), the Swiss Cancer Research Foundation (Grant no. KFS-4094-02-2017) and the Novartis Foundation for Biomedical Research.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.